House
Sign inCreate account
Drug lookup
Drug reference

infigratinib

FGFR1–3 kinase inhibitor · Antineoplastic agent

FGFR1–3 kinase inhibitorAntineoplastic agent
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
—
none in our sources
PREGNANCY
D
FDA category + note

Mechanism

Infigratinib is an orally bioavailable selective FGFR1–3 kinase inhibitor.

Indications

pretreated, locally advanced, or metastatic cholangiocarcinoma with an FGFR2 fusion or rearrangement

Pharmacokinetics

Half-life
33.5 h
Metabolism
CYP3A

Side effects

Common
diarrheahyperphosphatemia (resulting in soft-tissue mineralization and vascular and myocardial calcification)
Serious
  • ocular toxicity

Pregnancy & lactation

Pregnancy

D

Related guidelines

Blood transfusion in obstetrics and gynaecology
FOGSI · Obstetrics & Gynaecology · 2024
Heart failure in diabetes
RSSDI · Cardiology · 2023
Beta thalassaemia
ICMR · Hematology · 2022
Hypertension in adults
ICMR · Cardiology · 2019
Hypertrophic cardiomyopathy
ESC · Cardiology · 2026

Other FGFR1–3 kinase inhibitor drugs

pemigatinib
0 brands

Ask House about infigratinib

Continue into a citation-backed clinical answer with the drug context already attached.

Open in workspaceAsk House about this drug

Sources: Goodman & Gilman 14e·Verified: 2026-05-10 · House clinical team